信达生物(01801.HK)治疗淋巴瘤新药获批准在中国上市
信达生物(01801.HK)公布,公司与礼来制药共同开发的重组人-鼠嵌合抗CD20单克隆抗体药物达伯华(利妥昔单抗生物类似药,英文商标HALPRYZA)正式获得国家药品监督管理局在中国上市的批准,用於治疗弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤及慢性淋巴细胞性白血病。是继达伯舒(信迪利单抗注射液)、达攸同(贝伐珠单抗生物类似药)及苏立信(阿达木单抗生物类似药)之後,公司第四个获得国家药监局上市批准的单克隆抗体药物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.